Ligand Pharmaceuticals Incorporated
LGND
Classement en actions
#3097
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity,... Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Prix de l'action
$291.18
Dernière synchronisation: 2026-07-31
Capitalisation boursière
$5.84B
Changement (1 jour)
-1.73%
Changement (1 an)
55.99%
Pays
US
Échange Ligand Pharmaceuticals Incorporated (LGND)
Catégorie
Healthcare
Ratio P/E pour Ligand Pharmaceuticals Incorporated (LGND)
Ratio P/E au October 2026 TTM : 29.47
Selon les derniers rapports financiers et le cours de l'action de Ligand Pharmaceuticals Incorporated, le ratio P/E actuel (TTM) est de 29.47. À la fin de l’année 2023, le P/E de l’entreprise était de 23.69.
Historique du ratio P/E pour Ligand Pharmaceuticals Incorporated de 2000 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | 29.47 | -106.06% |
| 2024 | -486.05 | -2,151.90% |
| 2023 | 23.69 | -170.13% |
| 2022 | -33.78 | -175.13% |
| 2021 | 44.96 | -108.34% |
| 2020 | -539.23 | -17,229.80% |
| 2019 | 3.15 | -86.17% |
| 2018 | 22.77 | -90.07% |
| 2017 | 229.37 | -117.73% |
| 2016 | -1.29K | -15,615.10% |
| 2015 | 8.34 | -90.77% |
| 2014 | 90.36 | -3.41% |
| 2013 | 93.55 | -112.45% |
| 2012 | -751.68 | -3,378.49% |
| 2011 | 22.93 | -264.01% |
| 2010 | -13.98 | -88.91% |
| 2009 | -126.08 | 4,626.87% |
| 2008 | -2.67 | -258.53% |
| 2007 | 1.68 | -106.05% |
| 2006 | -27.81 | 96.61% |
| 2005 | -14.14 | -25.56% |
| 2004 | -19.00 | -31.44% |
| 2003 | -27.72 | 290.20% |
| 2002 | -7.10 | -53.97% |
| 2001 | -15.43 | 129.72% |
| 2000 | -6.72 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| 28.78 | -2.33% |
US
|
|
| -28.36 | -196.23% |
US
|
|
| -24.57 | -183.36% |
AU
|
|
| 30.33 | 2.92% |
NL
|
|
| - | - |
CH
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.